Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.

The British legal system, respected and emulated around the world, is an adversarial one where the defence and the prosecution face off in a battle of words. I am starting to think that the battle for investors' money is also adversarial with the companies putting out statements that should be interrogated and challenged. When these statements aren't challenged, investors can become the collateral damage.

Medicare price renegotiation and the FTC’s scrutiny of biopharma acquisitions have suppressed sector stock prices. But the sector may not be the actual target.